Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman, will deliver the company presentation on January 28 at 9:00 AM ET in Borgata Hotel Room #1, and management will be available for one-on-one investor meetings during the event.
The company noted completion of treatment in the Phase 1b trial for PH-762 and emphasized ongoing development of therapeutics using its proprietary INTASYL gene silencing technology targeting cancer.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: PHGE up 10.16%, while ADAP and APLM are down 17.57% and 2.49% respectively. Momentum scanner only flags SNSE down 6.16%, suggesting PHIO’s modest 0.93% gain is more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Clinical data update | Positive | -5.3% | Reported 70% overall response in PH-762 cutaneous carcinoma Phase 1b trial. |
| Jan 15 | Investor conference | Neutral | +0.9% | Announced Sidoti Micro-Cap conference presentation and PH-762 clinical update access. |
| Dec 23 | Regulatory progress | Positive | -6.4% | FDA accepted PH-762 nonclinical protocol; interim Phase 1b responses reported. |
| Nov 25 | Trial enrollment | Positive | +3.5% | Completed enrollment in Phase 1b trial of PH-762 for multiple skin cancers. |
| Nov 17 | Scientific presentation | Positive | +1.5% | Announced podium talk on INTASYL siRNA drug technology at industry congress. |
Positive PH-762 clinical updates have sometimes seen negative next-day reactions, while event and presentation news tends to align with modest gains.
Over recent months, Phio has steadily advanced its INTASYL siRNA program, especially lead candidate PH-762. Enrollment completion in the Phase 1b trial and multiple data readouts highlighted favorable safety and notable response rates, yet shares fell 5.26% and 6.36% after some strong updates. In contrast, news on conference and podium presentations (e.g., Nov 17, 2025 and Jan 15, 2026) aligned with small gains. Today’s DealFlow conference participation fits this pattern of investor-relations events following clinical milestones.
Regulatory & Risk Context
An effective resale S-3 covers up to 11,763,800 shares underlying outstanding warrants. Existing stockholders, not the company, may resell these shares. Phio would receive up to $24.5 million only upon full cash exercise of the warrants, with proceeds intended for working capital and PH-762 development. No primary share sales are registered under this prospectus.
Market Pulse Summary
This announcement highlights Phio’s continued investor-outreach efforts, with management presenting at the DealFlow Discovery Conference and emphasizing completion of treatment in the Phase 1b PH-762 skin cancer trial. Recent filings detailed a Q3 2025 net loss of $2.392 million, cash of $10.705 million, and a resale S-3 for 11,763,800 warrant shares with up to $24.5 million in potential proceeds. Investors may watch upcoming extended safety follow-up and follow-on trial design milestones for PH-762.
Key Terms
sirna medical
phase 1b medical
AI-generated analysis. Not financial advice.
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ET
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.
Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be available for one-on-one investor meetings throughout the event.
"All investors are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Completion of treatment in the Phase 1b trial for PH-762 marks a significant step forward in advancing a promising treatment option for skin cancer."
Event Details are as follows:
3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino & Spa
Atlantic City, NJ
January 28-29, 2026
Investors interested in scheduling a meeting with Phio Pharmaceuticals management team can register (Investors - DealFlow Discovery Conference) to attend the conference at no cost.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281484
FAQ
When is Phio Pharmaceuticals (PHIO) presenting at the DealFlow Discovery Conference?
Where is the 3rd Annual DealFlow Discovery Conference where PHIO will present?
How can investors schedule a meeting with Phio Pharmaceuticals management at the conference?
What clinical update did Phio Pharmaceuticals (PHIO) mention in the announcement?
What technology does Phio Pharmaceuticals use for its cancer therapeutics?
